Navigation Links
Hormone Therapy May Fight Resistant Prostate Cancer

Experimental treatment offers hope against cancer that returns after castration

WEDNESDAY, April 14 (HealthDay News) -- Preliminary research suggests that a new hormone treatment could be a weapon for doctors in the battle against a form of prostate cancer that's resistant to surgical removal of the testicles.

Only two of the three phases of research required for new drug treatments have been completed, however. At this point, it's not clear whether the treatment will go on to receive federal approval.

The hormone treatment, called MDV3100, is being tested as a treatment for a disease known as castration-resistant prostate cancer, according to a report on the research, published online April 14 in The Lancet.

Prostate tumors need testosterone to grow. One treatment involves castration, possibly with additional drug treatment, to combat the body's processing of testosterone.

Though the treatment kills some cancer cells, others remain alive but dormant, the researchers explained in a news release from the journal. And these cells can re-grow and survive without as much testosterone, thus becoming castration-resistant, they said.

For their study, Dr. Howard Scher of Memorial Sloan-Kettering Cancer Center in New York City and his colleagues tested the MDV3100 hormone treatment in 140 men in the United States with castration-resistant prostate cancer. The researchers gave varying doses, from 30 to 600 milligrams a day, to the men to find the maximum tolerable dose, which they determined to be 240 milligrams.

"We recorded encouraging anti-tumor activity with MDV3100 in patients with castration-resistant prostate cancer," both before and after chemotherapy, the researchers wrote in their report.

The researchers have begun a third phase of testing in which they will compare the hormone treatment to a placebo to see if it helps men with advanced prostate cancer live longer.

More information

For more about prostate cancer, visit the U.S. National Cancer Institute.

-- Randy Dotinga

SOURCE: The Lancet, news release, April 14, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Hormones Tied to Diabetes Might Also Influence Fertility
2. Anti-aging hormones: Little or no benefit and the risks are high
3. Demonstrated in vivo the transfer of maternal thyroid hormones to the fetus
4. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
5. Promising hormone may help reduce malnutrition in gastric cancer patients
6. Hormone Replacement Might Relieve Arthritis
7. Hormone replacement in joint fluid has potential regenerative effect
8. Another perk of painkillers? Decreased hormone levels may reduce cancer risk
9. Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms*
10. Thyroid hormone analogue for treating high cholesterol
11. Thyroid Hormone Analogue for Treating High Cholesterol
Post Your Comments:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
Breaking Medicine Technology: